Therapies targeting the TIGIT and STING pathways hold therapeutic promise
Safety and efficacy data of some novel immunotherapy agents are encouraging, but more research is needed to identify biomarkers and the optimal treatment schedule
An ESMO study reveals that poor quality of real-world data from oncology studies is still an issue
Scarcity of prospective data was reported as well as a limited use of real-world evidence as definitive evidence to regulatory approval decisions of targeted therapies in Europe
The future of real-world research is now
ESMO is at the forefront of digital oncology, with some initiatives that support oncologists navigating the emerging opportunities in the field of real-world data research
The emerging role of ctDNA in breast cancer
Liquid biopsies hold great promise in precision medicine in breast cancer, as shown by the pioneering work of Prof. Nicholas Turner, recipient of the ESMO Award for Translational Research 2023
Cancer Research
On the horizon of translational research
Tumour agnostic targeted agents and ‘smarter’ dynamic designs are two major areas of interest leading to more patient-centric approaches in cancer care
“Green” prescribing may limit the environmental impact of oncology
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
Early-phase data from targeting HER3 with ADC are encouraging
Some studies presented suggest preliminary activity of patritumab–deruxtecan in patients with HR-positive/HER2-negative disease and triple-negative breast cancer
Extended safety information and PROs data support key trial results in metastatic breast cancer
Data presentations from DESTINY-Breast04, DESTINY-Breast02 and EMERALD trials confirm the value of trastuzumab deruxtecan and elacestrant in this setting, despite moderate drop-out rates for PROs
Breast cancer leads the way in ADC therapy
Lessons learned from the use of second-generation antibody–drug conjugates (ADCs) in breast cancer can direct treatment in other tumour types
Cemiplimab survival improvements in NSCLC are durable
Extended analyses from two regulatory phase III trials show that the benefits of anti-PD-1-based therapy persist long term, even in patients with brain metastases